Cytokinetics

Cytokinetics

Yahoo Finance • 9 days ago

iShares Russell 2000 Value vs. Morningstar Small Cap: Which ETF Suits Your Portfolio Best?

Investors choosing between iShares Morningstar Small Cap Value ETF (NYSEMKT:ISCV) and iShares Russell 2000 Value ETF (NYSEMKT:IWN) must weigh the former's significantly lower expense ratio against the latter's massive liquidity and higher... Full story

Yahoo Finance • 9 days ago

Cytokinetics Announces Three Late-Breaking Science Abstracts at the European Society of Cardiology (ESC) Congress 2026

Hot Line Presentation of Primary Results from ACACIA-HCM to Elaborate on Positive Topline Results in Patients with Non-Obstructive Hypertrophic Cardiomyopathy Company to Host In-Person and Virtual Investor Event to Discuss Results from La... Full story

Yahoo Finance • 10 days ago

Which Is the Better Long-Term Buy: iShares' Small-Cap IWM or Invesco's Tech-Heavy QQQ?

Key Points iShares Russell 2000 ETF targets small-cap growth and value stocks, while Invesco QQQ Trust, Series 1 focuses on the largest non-financial leaders on the Nasdaq. Invesco QQQ Trust, Series 1 carries a slightly lower expense rati... Full story

Yahoo Finance • 11 days ago

Citi's picks and pans for H2 '26: REITs, tech, consumer, health

[Citibank headquarters in Canary Wharf, London, UK] VV Shots Citi released its roadmap for the second half of 2026, including a macro-to-micro view of equity sectors. "Our recently revised S&P 500 (SPY [https://seekingalpha.com/symbol/SP... Full story

Yahoo Finance • 12 days ago

Which iShares Value ETF Is Better, the Small Cap-Focused IWN or IJJ Targeting Mid-Cap Stocks?

While the iShares S&P Mid-Cap 400 Value ETF (NYSEMKT:IJJ) focuses on mid-sized companies, the iShares Russell 2000 Value ETF (NYSEMKT:IWN) offers exposure to small-cap value stocks with a broader portfolio and slightly higher costs. Both... Full story

Yahoo Finance • 17 days ago

Is Cytokinetics, Incorporated (CYTK) A Good Stock To Buy Now?

Is CYTK a good stock to buy? We came across a bullish thesis on Cytokinetics, Incorporated on TradersPro's Substack. In this article, we will summarize the bulls' thesis on CYTK. Cytokinetics, Incorporated's share was trading at $78.78 as... Full story

Yahoo Finance • 21 days ago

3 Under-the-Radar Biotech Takeover Targets for the Next Pharma Buying Spree

Quick Read Crinetics Pharmaceuticals leads as the cleanest buyout candidate at $3.79 billion; Cytokinetics' FDA-approved Myqorzo attracts Bristol Myers Squibb or Novartis but costs $10.86 billion. ARWR's ARO-INHBE nearly doubled tirzepati... Full story

Yahoo Finance • last month

Cytokinetics (CYTK) Launches MYQORZO in Germany for Obstructive HCM Treatment

Cytokinetics (NASDAQ:CYTK) is one of the most promising mid-cap stocks to buy according to analysts. On June 1, Cytokinetics announced the first commercial European launch of MYQORZO (aficamten) in Germany for the treatment of symptomatic... Full story

Yahoo Finance • last month

Cytokinetics Launches MYQORZO® (aficamten) in European Union, with First Commercial Availability in Germany

European Launch Follows Strong U.S. Start SOUTH SAN FRANCISCO, Calif., and ZUG, Switzerland, June 01, 2026 (GLOBE NEWSWIRE) -- Cytokinetics, Incorporated (Nasdaq: CYTK) today announced the first commercial European launch of MYQORZO® (a... Full story

Yahoo Finance • last month

Cytokinetics bringt MYQORZO® (aficamten) in der Europäischen Union auf den Markt; der erste kommerzielle Vertrieb erfolgt in Deutschland

Auf den erfolgreichen Start in den USA folgt nun die Markteinführung in Europa SOUTH SAN FRANCISCO, Kalifornien, und ZUG, Schweiz, June 01, 2026 (GLOBE NEWSWIRE) -- Cytokinetics, Incorporated (Nasdaq: CYTK) gab heute die erste kommerzie... Full story

Yahoo Finance • 2 months ago

StubHub, Jazz Pharmaceuticals upgraded: Wall Street's top analyst calls

The most talked about and market moving research calls around Wall Street are now in one place. Here are today's research calls that investors need to know, as compiled by The Fly. Top 5 Upgrades: Guggenheim upgraded StubHub (STUB) to... Full story

Yahoo Finance • 2 months ago

Identifix’s Direct-Hit® Mobile Brings OEM Repair Manuals to the Bay, Transforms How Repairs Get Done

Solera Global Corp. WESTLAKE, Texas, May 11, 2026 (GLOBE NEWSWIRE) -- Solera, a global leader in data-driven vehicle lifecycle solutions, in partnership with CYTK Inc., today announced a major upgrade to Direct-Hit Mobile that delivers of... Full story

Yahoo Finance • 2 months ago

Cytokinetics prices upsized $700M equity raise at $71 per share

* Cytokinetics (CYTK [https://seekingalpha.com/symbol/CYTK]) priced [https://seekingalpha.com/pr/20504697-cytokinetics-announces-pricing-of-upsized-public-offering-of-common-stock] an upsized underwritten public offering of 9.86M shares... Full story

Yahoo Finance • 2 months ago

Cytokinetics Announces Pricing of Upsized Public Offering of Common Stock

SOUTH SAN FRANCISCO, Calif., May 06, 2026 (GLOBE NEWSWIRE) -- Cytokinetics, Incorporated (Nasdaq: CYTK) today announced the pricing of an underwritten public offering of 9,859,155 shares of its common stock at a price to the public of $7... Full story

Yahoo Finance • 3 months ago

Catalyst Watch: OPEC meeting, FedEx talks freight, inflation reads, and SpaceX IPO buzz

[Wall street and Broadway road sign in New York City] Welcome to Seeking Alpha's Catalyst Watch - a breakdown of some of next week's actionable events that stand out. Read more about the events that may impact stock prices next week. SUN... Full story

Yahoo Finance • 4 months ago

Biohaven Stock Down 70% but One Fund's New $6 Million Bet Signals Turnaround Potential

Sarissa Capital Management established a new position in Biohaven Ltd.(NYSE:BHVN) during the fourth quarter, acquiring 513,184 shares worth $5.79 million at quarter’s end, according to a February 17, 2026, SEC filing. What happened Accor... Full story

Yahoo Finance • 4 months ago

DAFNA Capital Trims iShares Biotechnology ETF Within Broader Biotech Portfolio, According to Recent SEC Filing

What happened According to an SEC filing dated February 17, 2026, DAFNA Capital Management LLC reduced its stake in iShares Biotechnology ETF(NASDAQ:IBB) by 34,405 shares during the fourth quarter of 2025. The fund’s quarter-end IBB posit... Full story

Yahoo Finance • 4 months ago

Assessing Cytokinetics (CYTK) Valuation After Recent Share Price Weakness And Aficamten Expectations

Track your investments for FREE with Simply Wall St, the portfolio command center trusted by over 7 million individual investors worldwide. Cytokinetics stock overview Cytokinetics (CYTK) has been drawing attention as investors reassess... Full story

Yahoo Finance • 5 months ago

Cytokinetics aims for over 50% new patient share for MYQORZO by end of 2026 as global commercial launch accelerates

Earnings Call Insights: Cytokinetics (CYTK) Q4 2025 MANAGEMENT VIEW * Robert I. Blum, CEO, stated that "the fourth quarter of 2025 marked a defining moment for Cytokinetics with the FDA approval of MYQORZO for the treatment of adults w... Full story

Yahoo Finance • 5 months ago

Cytokinetics Announces European Commission Approval of MYQORZO® (aficamten) for the Treatment of Adults with Symptomatic Obstructive Hypertrophic Cardiomyopathy

Cytokinetics, Incorporated European Commission Approval Based on Results of SEQUOIA-HCM First European Launch Expected in Germany in Q2 2026 SOUTH SAN FRANCISCO, Calif., Feb. 17, 2026 (GLOBE NEWSWIRE) -- Cytokinetics, Incorporated (Nasd... Full story